Enfusion Inc. (ENFN)
NYSE NYSE Primary 
Levi & Korsinsky Reminds Shareholders of an Investigation into Enfusion, Inc. (ENFN) Regarding Potential Securities Fraud Allegations
NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
ENFN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 16, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Investors Invited To Join The Securities Fraud Investigation Of Enfusion, Inc. By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ATTENTION ENFN SHAREHOLDERS: Investors who lost money on Enfusion, Inc. are urged to contact Levi & Korsinsky about an ongoing investigation
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
ENFN INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Shareholders to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 15, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Enfusion Inc Investors Urged To Participate In Securities Fraud Investigation Led By The Schall Law Firm
LOS ANGELES, CA / ACCESSWIRE / August 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
ENFN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Investors to Contact the Firm
NEW YORK, NY / ACCESSWIRE / August 14, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
Enfusion Inc Investors Encouraged To Join Securities Fraud Investigation Led By The Schall Law Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.
Enfusion, Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - ENFN
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Enfusion, Inc. - ENFN
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Enfusion, Inc. ("Enfusion" or the "Company") (NYSE:ENFN). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Enfusion, Inc. (ENFN) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Enfusion, Inc. ("Enfusion") (NYSE:ENFN) concerning possible violations of federal securities laws. Enfusion conducted its initial public offering ("IPO") on or around October 21, 2021, selling 15.32 million shares of stock priced at $17.00 per share.
ENFN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Enfusion, Inc. and Encourages Investors to Contact the Firm!
NEW YORK, NY / ACCESSWIRE / August 13, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Enfusion, Inc. ("Enfusion" or "the Company") (NYSE:ENFN). Investors who purchased Enfusion securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/ENFN.
